...
首页> 外文期刊>American Journal of Pathology >Selectivity of Recombinant Human Leukotriene D4, Leukotriene B4, and Lipoxin A4 Receptors with Aspirin-Triggered 15-epi-LXA4 and Regulation of Vascular and Inflammatory Responses
【24h】

Selectivity of Recombinant Human Leukotriene D4, Leukotriene B4, and Lipoxin A4 Receptors with Aspirin-Triggered 15-epi-LXA4 and Regulation of Vascular and Inflammatory Responses

机译:重组人白三烯D4,白三烯B4和Lipoxin A4受体与阿司匹林触发的15-epi-LXA4的选择性以及血管和炎症反应的调节

获取原文
获取原文并翻译 | 示例
           

摘要

Aspirin-triggered lipoxin A4 (ATL, 15-epi-LXA4) and leukotriene D4 (LTD4) possess opposing vascular actions mediated via receptors distinct from the LXA4 receptor (ALX) that is involved in leukocyte trafficking. Here, we identified these receptors by nucleotide sequencing and demonstrate that LTD4 receptor (CysLT1) is induced in human vascular endothelia by interleukin-1ß. Recombinant CysLT1 receptor gave stereospecific binding with both [3H]-LTD4 and a novel labeled mimetic of ATL ([3H]-ATLa) that was displaced with LTD4 and ATLa (IC50 0.2 to 0.9 nmol/L), but not with a bioinactive ATL isomer. The clinically used CysLT1 receptor antagonist, Singulair, showed a lower rank order for competition with [3H]-ATLa (IC50 8.3 nmol/L). In contrast, LTD4 was an ineffective competitive ligand for recombinant ALX receptor with [3H]-ATLa, and ATLa did not compete for [3H]-LTB4 binding with recombinant LTB4 receptor. Endogenous murine CysLT1 receptors also gave specific [3H]-ATLa binding that was displaced with essentially equal affinity by LTD4 or ATLa. Systemic ATLa proved to be a potent inhibitor (>50%) of CysLT1-mediated vascular leakage in murine skin (200 µg/kg) in addition to its ability to block polymorphonuclear leukocyte recruitment to dorsal air pouch (4 µg/kg). These results indicate that ATL and LTD4 bind and compete with equal affinity at CysLT1, providing a molecular basis for aspirin-triggered LXs serving as a local damper of both vascular CysLT1 signals as well as ALX receptor-regulated polymorphonuclear leukocyte traffic.
机译:阿司匹林触发的脂蛋白A 4 (ATL,15-epi-LXA 4 )和白三烯 D 4 (LTD 4 )具有与白细胞 4 受体(ALX)不同的受体 介导的相反的血管动作>贩运。在这里,我们通过核苷酸 测序鉴定了这些受体,并证明了在 中诱导了LTD 4 受体(CysLT 1 )。白细胞介素-1β诱导人血管内皮细胞的生长。重组 CysLT 1 受体与[ 3 H] -LTD 4 以及一种新的标记的ATL([ 3 H] -ATLa)模拟物,该模拟物被LTD 4 和ATLa(IC 50 0.2至0.9 nmol / L),但不具有生物惰性的 ATL异构体。临床上使用的CysLT 1 受体拮抗剂 Singulair与[ 3 H] -ATLa 的竞争等级较低。 sup>(IC 50 8.3 nmol / L)。相比之下,LTD 4 对具有[ 3 H] -ATLa和ATLa 的重组ALX受体是无效的竞争性 配体。 sup>没有竞争与重组LTB 4 受体的[ 3 H] -LTB 4 结合。内源性鼠CysLT 1 受体也产生了特定的 [ 3 H] -ATLa结合,并以基本相等的 亲和力置换了由LTD 4 或ATLa。全身性ATLa被证明是CysLT 1 介导的鼠 皮肤中血管渗漏的有效 抑制剂(> 50%)(200 µg / kg)除了具有阻止多形核白细胞招募至背气囊(4 µg / kg)的能力外。这些结果 表明ATL和LTD 4 与CysLT 1 具有相等的亲和力 竞争,提供了分子基础阿司匹林触发的 LXs作为血管CysLT 1 信号 以及ALX受体调节的多形核白细胞 < / sup>流量。

著录项

  • 来源
    《American Journal of Pathology》 |2001年第1期|3-9|共7页
  • 作者单位

    From the Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia, Perioperative and Pain Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts;

    From the Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia, Perioperative and Pain Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts;

    From the Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia, Perioperative and Pain Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts;

    From the Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia, Perioperative and Pain Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts;

    From the Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia, Perioperative and Pain Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号